Last reviewed · How we verify
standard medical therapy
Standard medical therapy refers to the established, evidence-based treatment protocols and interventions currently recommended for a given disease or condition.
At a glance
| Generic name | standard medical therapy |
|---|---|
| Also known as | Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide., DRV/c+TDF/FTC, INSTI, Guideline- driven standard medical therapy, evidence-based therapy for heart failure |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Standard medical therapy encompasses the conventional pharmacological and non-pharmacological treatments that have demonstrated efficacy and safety in clinical practice and are widely accepted as first-line or guideline-recommended approaches. This is not a specific drug but rather a category of accepted clinical care that varies by indication and institution.
Approved indications
Common side effects
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- Ablation Versus Medical Management of Atrial Fibrillation in HFpEF (NA)
- Exercise for the Treatment of Cancer-Related Sarcopenia (NA)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: